Inhaled anticholinergics v placebo or active drugs (control) in patients with chronic obstructive pulmonary disease*
| Outcomes | Number of trials (n) | Weighted event rates | At 6 weeks to 5 years | ||
| Anticholinergics | Control | RRI (95% CI) | NNH (CI) | ||
| Major cardiovascular event† | 17 (14 783) | 1.9% | 1.2% | 58% (21 to 106) | 147 (80 to 404) |
| Myocardial infarction | 11 (10 598) | 1.3% | 0.8% | 53% (5 to 123) | 228 (98 to 2410) |
| Stroke | 7 (9251) | 0.6% | 0.4% | 46% (−19 to 162) | Not significant |
| Cardiovascular death | 12 (12 376) | 0.9% | 0.5% | 80% (17 to 177) | 250 (113 to 1177) |
| All-cause death | 17 (14 783) | 2.0% | 1.6% | 26% (−1 to 61) | Not significant |
-
*Abbreviations defined in glossary. Weighted event rates, RRI, NNH, and CI calculated from data in article using a fixed-effect model.
-
†Myocardial infarction, stroke, or cardiovascular death.
-
*Abbreviations defined in glossary. Weighted event rates, RRI, NNH, and CI calculated from data in article using a fixed-effect model.
-
†Myocardial infarction, stroke, or cardiovascular death.
